The European Patent Office (EPO) has concluded to uphold the validity of the main application patent for the use of isoflavones in consumer products. This patent is part of a series of Intellectual Properties (IPs) related to isoflavones that covers the use of isoflavones for major health indications. Health ingredients manufacturer Frutarom, with headquarters in Israel, is the sole licensee for this patent for isoflavones sourced from soy germ, with its SoyLife products. Frutarom congratulates the patent holder Novogen Research with the conclusion of the EPO, upholding the validity of this patent.
The Patent EP 0656786 covers the use of the isoflavones genistein, daidzein and their natural derivatives for health indications such as menopausal symptoms and pre-menstrual syndrome (PMS). Consumer products containing from 20 to 200 mg (daily dosage) of isoflavones that are marketed for these health indications may fall under the protection of this patent. Women’s health